These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 9857893

  • 1. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
    Bustos C, Hernández-Presa MA, Ortego M, Tuñón J, Ortega L, Pérez F, Díaz C, Hernández G, Egido J.
    J Am Coll Cardiol; 1998 Dec; 32(7):2057-64. PubMed ID: 9857893
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.
    Hernández-Presa MA, Martín-Ventura JL, Ortego M, Gómez-Hernández A, Tuñón J, Hernández-Vargas P, Blanco-Colio LM, Mas S, Aparicio C, Ortega L, Vivanco F, Gerique JG, Díaz C, Hernández G, Egido J.
    Atherosclerosis; 2002 Jan; 160(1):49-58. PubMed ID: 11755922
    [Abstract] [Full Text] [Related]

  • 3. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
    Ortego M, Bustos C, Hernández-Presa MA, Tuñón J, Díaz C, Hernández G, Egido J.
    Atherosclerosis; 1999 Dec; 147(2):253-61. PubMed ID: 10559511
    [Abstract] [Full Text] [Related]

  • 4. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
    Alfon J, Guasch JF, Berrozpe M, Badimon L.
    Atherosclerosis; 1999 Aug; 145(2):325-31. PubMed ID: 10488960
    [Abstract] [Full Text] [Related]

  • 5. HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
    Martínez-González J, Alfón J, Berrozpe M, Badimon L.
    Atherosclerosis; 2001 Nov; 159(1):27-33. PubMed ID: 11689203
    [Abstract] [Full Text] [Related]

  • 6. Atorvastatin attenuates inflammatory infiltration and vascular remodeling in lung of hypercholesterolemia rabbits.
    Duan S, Zhang Y, Wu SJ, Jiang LZ, Zhang J, Gan Y, Chen P, Zhao SP, Li GY.
    Exp Lung Res; 2010 Dec; 36(10):573-92. PubMed ID: 21043990
    [Abstract] [Full Text] [Related]

  • 7. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
    Kolyada AY, Fedtsov A, Madias NE.
    Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492
    [Abstract] [Full Text] [Related]

  • 8. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month.
    Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-García B, Vega M, Serrano J, Ortega L, Hernández G, Tuñón J, Egido J.
    Stroke; 2005 Aug; 36(8):1796-800. PubMed ID: 16020773
    [Abstract] [Full Text] [Related]

  • 9. Atorvastatin induces thrombomodulin expression in the aorta of cholesterol-fed rabbits and in TNFalpha-treated human aortic endothelial cells.
    Lin SJ, Hsieh FY, Chen YH, Lin CC, Kuan II, Wang SH, Wu CC, Chien HF, Lin FY, Chen YL.
    Histol Histopathol; 2009 Sep; 24(9):1147-59. PubMed ID: 19609862
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
    Li J, Li JJ, He JG, Nan JL, Guo YL, Xiong CM.
    Cardiovasc Ther; 2010 Sep; 28(1):8-14. PubMed ID: 20074254
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
    Sun Y, Liu J, Yang B, Sai X, Li T, Wang D, Zhou R.
    APMIS; 2014 Jun; 122(6):556-64. PubMed ID: 24164644
    [Abstract] [Full Text] [Related]

  • 12. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
    Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F.
    Arterioscler Thromb Vasc Biol; 2003 Jan 01; 23(1):58-63. PubMed ID: 12524225
    [Abstract] [Full Text] [Related]

  • 13. Atorvastatin treatment prevents alterations in coronary smooth muscle nuclear Ca2+ signaling in diabetic dyslipidemia.
    Wamhoff BR, Dixon JL, Sturek M.
    J Vasc Res; 2002 Jan 01; 39(3):208-20. PubMed ID: 12097819
    [Abstract] [Full Text] [Related]

  • 14. Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis.
    Vidal C, Gómez-Hernández A, Sánchez-Galán E, González A, Ortega L, Gómez-Gerique JA, Tuñón J, Egido J.
    J Pharmacol Exp Ther; 2007 Jan 01; 320(1):108-16. PubMed ID: 17015640
    [Abstract] [Full Text] [Related]

  • 15. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
    Grothusen C, Bley S, Selle T, Luchtefeld M, Grote K, Tietge UJ, Drexler H, Schieffer B.
    Atherosclerosis; 2005 Sep 01; 182(1):57-69. PubMed ID: 16115475
    [Abstract] [Full Text] [Related]

  • 16. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS.
    Am J Cardiovasc Drugs; 2001 Sep 01; 1(6):411-20. PubMed ID: 14728000
    [Abstract] [Full Text] [Related]

  • 17. Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: modulation by atorvastatin.
    Muñoz-García B, Martín-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J, Blanco-Colio LM.
    Stroke; 2006 Aug 01; 37(8):2044-53. PubMed ID: 16809572
    [Abstract] [Full Text] [Related]

  • 18. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
    Waehre T, Damås JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE, Torsvik H, Frøland SS, Semb AG, Aukrust P.
    J Am Coll Cardiol; 2003 May 07; 41(9):1460-7. PubMed ID: 12742282
    [Abstract] [Full Text] [Related]

  • 19. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
    Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS.
    Nature; 2002 Nov 07; 420(6911):78-84. PubMed ID: 12422218
    [Abstract] [Full Text] [Related]

  • 20. Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries.
    Collin B, Busseuil D, Korandji C, Zeller M, Cottin Y, Duvillard L, Rioufol G, Pitois-Merli I, Rochette L.
    J Cardiovasc Pharmacol; 2006 Mar 07; 47(3):428-36. PubMed ID: 16633086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.